Finally began large-scale vaccine trials against HIV

On our portal we have already repeatedly told you that scientists generate different types of vaccines from one of the worst diseases on the planet — the human immunodeficiency virus (HIV). But then it was only a small development or laboratory tests. Now ready to test a new HIV vaccine on humans. And testing is not limited to a small group of people. The vaccine will be tested for a huge number of volunteers on three continents.

How does HIV vaccine

New drug is called “mosaic” vaccine (‘Mosaic’ HIV vaccine) and how it is arranged is in the title. It includes the genetic material of several strains of the human immunodeficiency virus. The vaccine itself is collected, roughly speaking, “piece by piece”, taking a portion from each strain of the virus and linking them together. That is, in the end, “collected” the vaccine consists of the hotel parts of the virus as assembled from pieces of the mosaic picture (you can also try to draw an analogy with the puzzle, but the essence does not change).

See also: How to use genetic engineering managed to defeat HIV.

According to the editors of the journal Nature, the basis of lies vaccines inactivated virus genome cold, in which is embedded three synthetic gene of HIV. They were created on the basis of strains detected in different regions of the globe. According to the scientists, “mosaic” vaccine has a fairly long lasting effect and can protect against more types of HIV.

When you start to test a vaccine against HIV

Phase clinical trials of new vaccines will begin in September 2019. Tests will take 3800 volunteers from 8 European countries and several countries in North and South America. The study will involve mainly transgender, homosexual and bisexual men, as the statistics show that these populations are most vulnerable to HIV.

Vaccination involves the introduction of four doses of vaccine, the last two of which are supplemented with synthetic proteins that increase the production of antibodies against human immunodeficiency virus. The introduction of the vaccine will occur within one year. Half of the subjects will receive 4 doses of this vaccine, and the other half a placebo. Of course, the participants will not know what they are getting.

Previous stages of testing confirmed that the “mosaic” vaccine causes a persistent immune response to HIV, and now scientists need to understand, does it provide long-term protection from the virus. Now scientists relevant to the project with optimism and hope that the vaccine will prove its effectiveness. However, the scientific community believes that HIV can rapidly mutate and acquire resistance to the “mosaic” vaccine.

To discuss this and other news, you can in our chat in Telegram.

Leave a Reply

Your email address will not be published. Required fields are marked *